You searched for "AMD"
New partnership to prevent unnecessary sight loss
Sight loss charity the Macular Society has announced a new partnership with OcuPlan, a service designed to give patients with long-term eye conditions such as macular disease affordable access to specialist care to prevent unnecessary sight loss.Newmedica calls for transparency over glaucoma waiting lists and more collaboration with community optometrists
Ophthalmology provider Newmedica is calling for greater transparency by all providers over glaucoma waiting lists to tackle a ‘postcode lottery’ facing patients. Coinciding with Glaucoma Awareness Week (30 June – 6 July), Newmedica, which provides NHS and private ophthalmology services,...It’s not all about ARED - Time for a pragmatic approach to nutrition for eye health?
Advances in treatment for retinal diseases involving neovascularisation have undoubtedly changed the future of eye care across the UK for the better, but also created great challenges for service delivery in ophthalmology, particularly within the NHS. Some statistics are starting...Update on emerging therapies for age-related macular degeneration
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...Considerations in the management of retinal disorders
Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...
Clinical outcomes of AMT in acute ocular chemical injury
This is a retrospective study of patients from two units in Germany and UK between 1998 and 2008. The ocular chemical burns were classified by Roper-Hall and Dua classifications. A total of 72 eyes of 54 patients aged 37.3 years...Patients blinded by stem cells! How safe are they really?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...
Efficacy and safety of intravitreal faricimab in nAMD, DME and RVO
This paper is an analysis of data extracted from 13 eligible studies in the context of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), collected from systematic literature search of MEDLINE, Embase, and Cochrane...AI can identify treatment gaps for patients with macular disease, study shows
Using artificial intelligence (AI) in eye clinics could reduce both undertreatment and overtreatment of neovascular or ‘wet’ age-related macular degeneration (AMD). AMD is the leading cause of irreversible vision loss in older people and accounts for around 1 in 10...
How many injections in nAMD: ranibizumab vs. aflibercept
Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...
Brolucizumab in age-related macular degeneration, HAWK Study
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
